Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Codexis, a Redwood City, Calif.-based biocatalyst technology developer, has licensed Dyadic International's Chrysosporium lucknowense fungus, or C1, expression system for the large-scale production of enzymes for making biofuels and chemical and pharmaceutical intermediates. Codexis will make an up-front payment of $10 million provided that certain performance criteria are satisfied. Based in Jupiter, Fla., Dyadic produces enzymes and other biomaterials using proprietary fungal strains.
This article has been sent to the following recipient: